無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ポイントオブケア (POC) 分子診断市場:製品/サービス別 (アッセイ、キット、分析装置、ソフトウェア)・用途別 (呼吸器疾患、院内感染)・技術別 (RT-PCR、INAAT)・エンドユーザー別 (開業医、ICU (集中治療室)) の将来予測 (2023年まで)

Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023

発行 MarketsandMarkets 商品コード 641511
出版日 ページ情報 英文 108 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.61円で換算しております。
Back to Top
ポイントオブケア (POC) 分子診断市場:製品/サービス別 (アッセイ、キット、分析装置、ソフトウェア)・用途別 (呼吸器疾患、院内感染)・技術別 (RT-PCR、INAAT)・エンドユーザー別 (開業医、ICU (集中治療室)) の将来予測 (2023年まで) Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023
出版日: 2018年05月17日 ページ情報: 英文 108 Pages
概要

世界のPOC分子診断検査市場は、2018年には7億2550万米ドル、2023年には14億4020万米ドルと、14.7%のCAGR (複合年間成長率) で成長する見通しです。市場成長の主な要因として、世界規模での感染症患者の増加や、分散型診断への関心増大、CLIA法準拠のPOC分子検査の需要増加などが挙げられます。地域別では、アジア太平洋地域での大幅な市場成長が見込まれています。

当レポートでは、世界のPOC (ポイントオブケア) 分子診断の市場について分析し、市場の基本構造や最新情勢、主な市場促進・阻害要因、市場動向の見通し (今後8年間分)、製品/サービス別・用途別・技術別・エンドユーザー別・地域別の詳細動向、市場競争の状態、主要企業のプロファイルなどを調査しております。

FIGURE 1 POC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2018 VS. 2023

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場のダイナミクス
    • 促進要因
      • 世界規模での感染症の蔓延
      • 分散型診断に対する関心の増大
      • CLIA (臨床検査室改善法) 準拠POC分子検査の需要増加
    • 抑制要因
      • 医療費償還制度の不備
      • 厳格で時間のかかる規制政策:製品上市サイクルを大きく遅延させる要因
    • 市場機会
      • 分子診断検査に関する研究開発 (R&D) 活動の活発化
      • 中国・インド・ブラジルでのPOC分子診断検査の普及率上昇

第6章 POC (ポイントオブケア) 分子診断市場:用途別

  • イントロダクション
    • 呼吸器疾患
    • 性感染症
    • 院内感染
    • 腫瘍
    • 肝炎
    • その他

第7章 POC分子診断市場:技術別

  • イントロダクション
  • RT-PCR法 (リアルタイムPCR (ポリメラーゼ連鎖反応))
  • INAAT法 (等温核酸増幅技術)
  • その他の技術

第8章 POC分子診断市場:製品・サービス別

  • イントロダクション
  • アッセイ (測定検査)、キット
  • 計測機器、分析装置
  • ソフトウェア、サービス

第9章 POC分子診断市場:エンドユーザー別

  • イントロダクション
  • 開業医
  • 病院:救急部門 (ED)、集中治療室 (ICU)
  • 研究機関
  • その他

第10章 POC分子診断市場:地域別

  • イントロダクション
  • 北米 (米国、カナダ)
  • 欧州
  • アジア太平洋地域
  • 他の国々 (RoW)

第11章 競争環境

  • 市場概況
  • 市場ランキング分析
  • 競争状況と動向
    • 製品上市・認証
    • 企業買収
    • 協力/合意/提携
    • 事業拡張

第12章 企業プロファイル (イントロダクション、製品・サービス、戦略、アナリストの考察、近年の動向、MnMの見解)

  • ABBOTT LABORATORIES
  • DANAHER CORPORATION
  • BIOMERIEUX SA
  • ROCHE DIAGNOSTICS
  • QUIDEL
  • MERIDIAN BIOSCIENCE
  • MESA BIOTECH
  • GENEPOC
  • DXNA
  • ATLAS GENETICS
  • SPARTAN BIOSCIENCE
  • BIOCARTIS

第13章 付録

図表

LIST OF TABLES

  • TABLE 1: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 2: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 3: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 4: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 5: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 6: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ASSOCIATED INFECTIONS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 7: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ASSOCIATED INFECTIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 9: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 11: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 12: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 13: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 14: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 15: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 16: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: PRODUCT APPROVALS IN THE LAST THREE YEARS
  • TABLE 18: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 19: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 20: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 21: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 22: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016-2023 (USD MILLION)
  • TABLE 23: POC MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 24: NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 25: POC MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 26: NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 27: POC MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 28: NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 29: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 30: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 31: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 32: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL EDS & ICUS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 33: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL EDS & ICUS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 34: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 35: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 36: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 37: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 38: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 39: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 40: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016-2023 (USD MILLION)
  • TABLE 41: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 42: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 43: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 44: US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016-2023 (USD MILLION)
  • TABLE 45: US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 46: US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 47: US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 48: CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016-2023 (USD MILLION)
  • TABLE 49: CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 50: CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 51: CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 52: EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016-2023 (USD MILLION)
  • TABLE 53: EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 54: EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 55: EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 56: APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 57: APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 58: APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 59: APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 60: ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 61: ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 62: ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 63: ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 64: RANK OF COMPANIES IN THE GLOBAL MOLECULAR POC DIAGNOSTIC MARKET, 2017
  • TABLE 65: PRODUCT LAUNCHES, 2015-2018
  • TABLE 66: ACQUISITIONS, 2015-2018
  • TABLE 67: COLLABORATIONS/PARTNERSHIPS/AGREEMENTS, 2015 & 2018
  • TABLE 68: EXPANSIONS, 2015 TO 2018

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION
  • FIGURE 6: POC MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018 VS. 2023
  • FIGURE 7: POC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018 VS. 2023
  • FIGURE 8: POC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018 VS. 2023
  • FIGURE 9: NORTH AMERICA TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET IN 2018
  • FIGURE 10: INCREASING WORLDWIDE PREVALENCE OF INFECTIOUS DISEASES, A KEY DRIVER FOR THE GROWTH OF THE POC MOLECULAR DIAGNOSTICS MARKET
  • FIGURE 11: ASSAYS & KITS TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET IN ASIA PACIFIC IN 2017
  • FIGURE 12: RESPIRATORY DISEASES TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 13: PHYSICIAN OFFICES TO DOMINATE THE POC MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: POC MOLECULAR DIAGNOSTIC MARKET: DRIVERS, RESTRAINTS, & OPPORTUNITIES
  • FIGURE 15: NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 16: APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 17: ABBOTT LABORATORIES: COMPANY SNAPSHOT ( 2017)
  • FIGURE 18: DANAHER CORPORATION: COMPANY SNAPSHOT (2017)
  • FIGURE 19: BIOMERIEUX SA: COMPANY SNAPSHOT (2017)
  • FIGURE 20: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017)
  • FIGURE 21: QUIDEL: COMPANY SNAPSHOT (2016)
  • FIGURE 22: MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2017)
  • FIGURE 23: BIOCARTIS: COMPANY SNAPSHOT (2017)
目次
Product Code: MD 6292

"The global POC molecular diagnostics market is projected to grow at a CAGR of 14.7%."

The global point of care (POC) molecular diagnostics market is expected to reach USD 1440.2 million by 2023 from USD 725.5 million in 2018, at a CAGR of 14.7%. Growth in the POC molecular diagnostics market is driven by the increasing prevalence of infectious diseases, rising focus on decentralized diagnostics, and the growing demand for CLIA-waived molecular POC tests. However, inadequate reimbursement and stringent regulatory policies are likely to restrain the growth of this market during the forecast period.

"The INAAT technology is expected to grow at highest CAGR during the forecast period."

Based on technology, the POC molecular diagnostics market is segmented into RT-PCR, INAAT, and other technologies. The INAAT segment is expected to grow at highest CAGR during the forecasted period. The increasing popularity of INAAT for infectious diseases diagnosis is expected to drive this market in the coming years.

"Asia Pacific is projected to grow at the highest CAGR during the forecast period."

While North America is expected to account for the largest share of the global POC molecular diagnostics market, Asia Pacific is projected to grow at the highest CAGR during the study period. The key factors influencing the growth of this market include growing initiatives by market players, rising demand for influenza A/B tests, decentralized healthcare delivery systems, and increasing patient population base in this region.

Break-up profile of primaries::

  • By Company Type- Tier 40%, Tier 30%, and Tier 30%
  • By Designation-C-level-27%, D-level-18%, and Others-55%
  • By Region-North America-50%, Europe-20%, Asia Pacific-20%, and RoW-10%

The key players in the global POC molecular diagnostics market are: Roche Diagnostics (Switzerland), Abbott Laboratories (US), Danaher (US), Biomerieux (France), and Meridian Biosciences (US).

Research Coverage:

The POC molecular diagnostics market in this report is segmented by product & service, application, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches & approvals, acquisition, collaborations, agreements, partnerships, and expansion, and profiles key players and their core competencies in the POC molecular diagnostics market.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on portfolios offered by the top players in the global POC molecular diagnostics market. The report analyzes the market by product & service, application type, technology, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global POC molecular diagnostics market
  • Market Development: Comprehensive information about lucrative emerging markets-the report analyzes the markets for POC molecular diagnostic products across regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global POC molecular diagnostics market
  • Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global POC molecular diagnostics market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. PRIMARY DATA
    • 2.1.1. KEY DATA FROM PRIMARY SOURCES
    • 2.1.2. KEY INDUSTRY INSIGHTS
  • 2.2. SECONDARY DATA
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
  • 2.3. MARKET SIZE ESTIMATION
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.4.1. ASSUMPTIONS FOR THE STUDY4

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. POC MOLECULAR DIAGNOSTICS MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: APAC POC MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY AND PRODUCT
  • 4.3. POC MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
  • 4.4. POC MOLECULAR DIAGNOSTICS MARKET, BY END USER

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing worldwide prevalence of infectious diseases
      • 5.2.1.2. Rising focus on decentralized diagnostics
      • 5.2.1.3. Growing demand for CLIA-waived molecular POC tests
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Inadequate reimbursements
      • 5.2.2.2. Stringent and time-consuming regulatory policies significantly increase the product launch cycle
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Growing R&D activities in molecular diagnostic testing
      • 5.2.3.2. Increasing penetration of POC molecular diagnostic tests in China, India, and Brazil

6. POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1. INTRODUCTION
    • 6.1.1. RESPIRATORY DISEASES
    • 6.1.2. SEXUALLY TRANSMITTED DISEASES
    • 6.1.3. HOSPITAL-ACQUIRED INFECTIONS
    • 6.1.4. ONCOLOGY
    • 6.1.5. HEPATITIS
    • 6.1.6. OTHER APPLICATIONS

7. POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. RT-PCR
  • 7.3. INAAT
  • 7.4. OTHER TECHNOLOGIES

8. POINT-OF-CARE (POC) MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 8.1. INTRODUCTION
  • 8.2. ASSAYS & KITS
  • 8.3. INSTRUMENTS/ANALYZERS
  • 8.4. SOFTWARE & SERVICES

9. POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PHYSICIAN OFFICES
  • 9.3. HOSPITAL EMERGENCY DEPARTMENTS & INTENSIVE CARE UNITS
  • 9.4. RESEARCH INSTITUTES
  • 9.5. OTHER END USERS

10. POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
    • 10.2.2. CANADA
  • 10.3. EUROPE
  • 10.4. ASIA PACIFIC
  • 10.5. ROW

11. COMPETITIVE LANDSCAPE

  • 11.1. MARKET OVERVIEW
  • 11.2. MARKET RANKING ANALYSIS, 2017
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. PRODUCT LAUNCHES AND APPROVALS
    • 11.3.2. ACQUISITIONS
    • 11.3.3. COLLABORATIONS/AGREEMENTS/PARTNERSHIPS
    • 11.3.4. EXPANSIONS

12. COMPANY PROFILE (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. ABBOTT LABORATORIES
  • 12.2. DANAHER CORPORATION
  • 12.3. BIOMERIEUX SA
  • 12.4. ROCHE DIAGNOSTICS
  • 12.5. QUIDEL
  • 12.6. MERIDIAN BIOSCIENCE
  • 12.7. MESA BIOTECH
  • 12.8. GENEPOC
  • 12.9. DXNA
  • 12.10. ATLAS GENETICS
  • 12.11. SPARTAN BIOSCIENCE
  • 12.12. BIOCARTIS

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS
  • 13.6. AUTHOR DETAILS
Back to Top